Literature DB >> 34146613

Whole genome sequencing of human metapneumoviruses from clinical specimens using MinION nanopore technology.

Kevin Groen1, Stefan van Nieuwkoop1, Theo M Bestebroer1, Pieter L Fraaij1, Ron A M Fouchier1, Bernadette G van den Hoogen2.   

Abstract

Human metapneumovirus (HMPV), a member of the Pneumoviridae family, is a causative agent of respiratory illness in young children, the elderly, and immunocompromised individuals. Globally, viruses belonging to two main genetic lineages circulate, A and B, which are further divided into four genetic sublineages (A1, A2, B1, B2). Classical genotyping of HMPV is based on the sequence of the fusion (F) and attachment (G) glycoprotein genes, which are under direct antibody-mediated immune pressure. Whole genome sequencing provides more information than sequencing of subgenomic fragments and is therefore a powerful tool for studying virus evolution and disease epidemiology and for identifying transmission events and nosocomial outbreaks. Here, we report a robust method to obtain whole genome sequences for HMPV using MinION Nanopore technology. This assay is able to generate HMPV whole genome sequences from clinical specimens with good coverage of the highly variable G gene and is equally sensitive for strains of all four genetic HMPV sublineages. This method can be used for studying HMPV genetics, epidemiology, and evolutionary dynamics.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Human metapneumovirus; MinION sequencing; Nanopore technology; Whole genome sequencing

Mesh:

Year:  2021        PMID: 34146613     DOI: 10.1016/j.virusres.2021.198490

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  1 in total

1.  An off-season outbreak of human metapneumovirus infections after ending of a COVID-19 lockdown.

Authors:  Cmhj Kivit; K Groen; M Jongbloed; Cfm Linssen; A van Loo; Ecm van Gorp; S van Nieuwkoop; Bg van den Hoogen; Md de Kruif
Journal:  J Infect       Date:  2022-02-03       Impact factor: 38.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.